Potent chemical chaperone compounds for GM1-gangliosidosis: N-substituted (+)-conduramine F-4 derivatives
- 4 November 2014
- journal article
- research article
- Published by Royal Society of Chemistry (RSC) in MedChemComm
- Vol. 6 (2) , 306-310
Abstract
The development of second-generation valienamine-type chemical chaperones for GM1-gangliosidosis is described. Several N-substituted (+)-conduramine F-4 derivatives were designed as novel chemical chaperones based on a lead chaperone compound, N-octyl-4-epi-β-valienamine, to decrease the inhibitory activity while increasing the enzyme enhancement activity. Among the derivatives synthesized during this study, a conduramine derivative with an N-cyclohexylmethyl group has demonstrated significant enhancement of R201C mutated β-galactosidase activity.Keywords
This publication has 25 references indexed in Scilit:
- Pharmacological Chaperones as Therapeutics for Lysosomal Storage DiseasesJournal of Medicinal Chemistry, 2013
- Evaluation of N-nonyl-deoxygalactonojirimycin as a pharmacological chaperone for human GM1 gangliosidosis leads to identification of a feline model suitable for testing enzyme enhancement therapyMolecular Genetics and Metabolism, 2012
- Tuning glycosidase inhibition through aglycone interactions: pharmacological chaperones for Fabry disease and GM1 gangliosidosisChemical Communications, 2012
- 1-Deoxy-d-galactonojirimycins with dansyl capped N-substituents as β-galactosidase inhibitors and potential probes for GM1 gangliosidosis affected cell linesCarbohydrate Research, 2011
- Identification and Characterization of Pharmacological Chaperones to Correct Enzyme Deficiencies in Lysosomal Storage DisordersASSAY and Drug Development Technologies, 2011
- DLHex-DGJ, a novel derivative of 1-deoxygalactonojirimycin with pharmacological chaperone activity in human GM1-gangliosidosis fibroblastsMolecular Genetics and Metabolism, 2010
- A counterintuitive approach to treat enzyme deficiencies: use of enzyme inhibitors for restoring mutant enzyme activityBiological Chemistry, 2007
- N-Octyl-β-valienamine up-regulates activity of F213I mutant β-glucosidase in cultured cells: a potential chemical chaperone therapy for Gaucher diseaseBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2004
- Chemical Modification of the β-Glucocerebrosidase Inhibitor N-Octyl-β-valienamine: Synthesis and Biological Evaluation of 4-Epimeric and 4-O-(β-?-Galactopyranosyl) DerivativesBioorganic & Medicinal Chemistry, 2002
- Aggregation of the Inactive Form of Human α-Galactosidase in the Endoplasmic ReticulumBiochemical and Biophysical Research Communications, 1996